Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > The recent Option Grant.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2401)
•••
Comment by JDavenporton Aug 13, 2022 7:43pm
155 Views
Post# 34894578

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:The recent Option Grant.

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:The recent Option Grant.Well, if there is one thing that DrDR is good at, it's dissembling, obfuscation, underestimating shareholders' intelligence, etc etc. She's too cute by half in her statements. Many of them can mean anything. I have a video recording of the webinaire if you want to listen to it again. I keep a record of that stuff because of the ambiguity of her statements. It is a mistake to think you can understand many of her statements in a literal way.

I've put my opinions on the record. I have expressed them as possibilities and likelihoods. They're based on what DrDR has said, not said, and how she has stated things.

And you've put your opinions on the record. I have no interest in agreeing to disagree. Frankly, I think the best is possible but that Bioasis is unlikely to achieve it.

Last word is yours.

jd
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities